logo
RFK Jr. calls for 'new' vaccines to undergo placebo-controlled trials

RFK Jr. calls for 'new' vaccines to undergo placebo-controlled trials

Yahoo02-05-2025
Health and Human Services Secretary Robert F. Kennedy Jr. will require new vaccines to undergo placebo testing, marking what a department spokesperson called "a radical departure from past practices."
The policy change would force vaccines, in order to be approved for human use, to undergo studies in which half of individuals in a study receive a placebo – typically a saline shot – to compare results against the vaccine.
Placebo-controlled trials are already used to test new drugs or vaccines for safety and efficacy, but some experts consider it unethical to conduct such trials when a vaccine or treatment is already considered safe and efficacious. For example, they say, giving half of the kids in a trial a placebo for the measles vaccine when an already proven vaccine exists would put those participants unnecessarily at risk for the virus.
It remains unclear what HHS considers a "new" vaccine and whether that includes the flu and COVID vaccines, which are updated on an annual basis to better protect against currently circulating strains.
"FDA Commissioner Dr. Marty Makary has indicated that significant updates to existing vaccines—such as those addressing seasonal strain changes or antigenic drift—may be considered 'new products' requiring additional clinical evaluation," the department spokesperson told ABC News.
MORE: RFK Jr. has a goal to study what's 'behind' autism by September. How realistic is it?
But the spokesperson indicated the yearly flu vaccine might not be affected by the policy, calling it "tried and tested for more than 80 years."
It appears, instead, that the policy could impact the rollout of future COVID vaccines, which are updated annually.
When asked to elaborate on what the department considers a "new" vaccine, the spokesperson said that federal health agencies would follow the "Gold Standard of Science".
Kennedy has long questioned the safety of vaccines and argued that placebo-based trials are needed to ensure vaccines aren't doing more harm than good.
Even as thousands were dying during the COVID-19 public health emergency, COVID vaccines still underwent placebo-controlled studies with more than 100,000 volunteers from diverse populations. Experts say the practice is necessary to determine if a vaccine is not only effective, but also safe.
MORE: RFK Jr. unveils plan to phase out 8 artificial food dyes in the US
Many childhood vaccines were originally tested with placebo trials. Others have been available for decades, providing data from millions of people showing those vaccines are overwhelmingly safe and effective.
Once a vaccine for a disease is approved safe and effective, future versions of the shot are tested in clinical trials against the already approved shot. Clinical trials test whether the updated vaccines generate an immune response that's comparable to or better than previous versions of the vaccine.
Even after vaccines are made available to the public, scientists continue to monitor them for safety. They also review any reports of side effects or reactions and share these facts with the public.
RFK Jr. calls for 'new' vaccines to undergo placebo-controlled trials originally appeared on abcnews.go.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Handsoaps Recalled Over Bacteria That Can Cause Sepsis
Handsoaps Recalled Over Bacteria That Can Cause Sepsis

Gizmodo

time7 minutes ago

  • Gizmodo

Handsoaps Recalled Over Bacteria That Can Cause Sepsis

Four brands of soap and skin products are being recalled by their manufacturer after they were discovered to potentially be contaminated with bacteria that can cause infections, and even lead to sepsis in immunosuppressed people, according to announcements from the FDA and DermaRite Industries. The products, DermaKleen, KleenFoam, DermaSarra, and PeriGiene, have been recalled nationwide in the U.S. and Puerto Rico over the bacteria Burkholderia cepacia (spelled as cepecia in the FDA press release), though the health agency didn't indicate how the contamination of the soaps may have occurred. The announcements from the FDA and DermaRite Industries also didn't state where the soaps and skin products were sold, though listings online suggest the soaps are often purchased by companies and institutions for use in public facilities. It's not clear how popular the products may be at physical retail stores where the average consumer might buy them for use in the home, though they are available at online retailers like Amazon. Neither DermaRite nor the FDA immediately responded to questions Monday. The FDA's description of the recalled products: 'In healthy individuals with minor skin lesions the use of the product will more likely result in local infections, whereas in immunocompromised individuals the infection is more likely to spread into blood stream leading to life-threatening sepsis,' the company said in a statement posted online. 'To date, DermaRite has not received any reports of adverse events related to this recall.' Consumers who believe they're experiencing issues after using these products are encouraged to contact their doctors. The lot numbers and expiration dates for the recalled products, according to DermaRite: Consumers who have questions about the recall are encouraged to call Mary Goldberg at DermaRite Industries at the number 973-569-9000 x104, Monday through Friday, from 9:00 am to 5:00 pm ET, according to the company's press release. The company can also be reached by email at: [email protected].

FDA Okays Ketamine-Based Med for Post-Surgical Pain
FDA Okays Ketamine-Based Med for Post-Surgical Pain

Medscape

time7 minutes ago

  • Medscape

FDA Okays Ketamine-Based Med for Post-Surgical Pain

The FDA has approved the racemic ketamine product known as KETARx (PharmaTher Holdings) for the treatment of post-surgical pain. 'This historic FDA approval…is a testament to years of dedicated development,' Fabio Chianelli, chairman and CEO of PharmaTher, said in a release. 'We remain steadfast in our mission to harness the pharmaceutical potential of ketamine for a range of mental health, neurological, and pain disorders,' he added. The company noted that it hopes to expand ketamine development into conditions such as Parkinson's disease, amyotrophic lateral sclerosis, depression, and complex regional pain syndrome. Its product has already received an orphan drug designation for the treatment of Rett syndrome. It added that, among psychedelic and 'psychedelic-adjacent' drugs, ketamine is the only one to be included on a list of Essential Medicines by the World Health Organization. The company initially announced that the FDA had set an approval goal date of April 2024 for KETARx. However, after 'minor deficiencies identified by Quality' were identified, the FDA assigned a new target date of October 2024. As reported by Medscape Medical News at the time, the FDA issued a complete response letter requesting additional information on the application. The final date of August 2025 was set after the company submitted the requested additional information.

Nationwide recall alert: Soap products may cause sepsis, life-threatening infections
Nationwide recall alert: Soap products may cause sepsis, life-threatening infections

Yahoo

time20 minutes ago

  • Yahoo

Nationwide recall alert: Soap products may cause sepsis, life-threatening infections

A voluntary recall has been initiated for certain soap products that could contain bacteria which can lead to 'life-threatening infections' including sepsis, according to the Food and Drug Administration (FDA). DermaRite Industries initiated the recall after discovering the products may be contaminated with Burkholderia Cepacia. This bacteria can cause local infections in healthy people with cuts, but it poses a serious risk to those with weakened immune systems, potentially leading to life-threatening sepsis if it enters the bloodstream. Exposure to Burkholderia Cepacia can lead to various symptoms from no symptoms at all to serious respiratory infections especially in patients with cystic fibrosis or other chronic lung disease, according to the Center for Disease Control (CDC). Other symptoms may include fever and fatigue. 'DermaRite has notified its distributors and customers by e-mail to immediately examine available inventory and destroy all affected products in accordance with each facility's process,' the statement reads. 'Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product.' The products being recalled are: DermaKleen, an over-the-counter healthcare antiseptic lotion soap with vitamin E DermaSarra, an over-the-counter gel used for temporary relief of itching associated with minor skin irritations due to dry skin, insect bites, detergents, sunburn KleenFoam, an over-the-counter foam soap with Aloe Vera used for handwashing PeriGiene, an over-the-counter antiseptic cleaner used for the perineal area The recalled products were distributed across the United States and in Puerto Rico, the FDA said. DermaRite had not received any reports of adverse events related to this recall. However, customers can report reactions or quality issues related to the products to FDA's MedWatch Adverse Event Reporting program either online or by mail or fax by downloading this form. More Business News Tobacco harvest in full swing at Wendolowski Farm in Hatfield (Photos) Popular regional bakery to close two Boston-area stores Say goodbye to your Hulu app - Disney is making a major change to how you'll stream in 2026 Walmart in Central Mass. looking to become supercenter Business Monday ETC: Aug. 11, 2025 Read the original article on MassLive. Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store